GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (HKSE:02315) » Definitions » PS Ratio

Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) PS Ratio : 4.51 (As of May. 29, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Biocytogen Pharmaceuticals (Beijing) Co's share price is HK$8.87. Biocytogen Pharmaceuticals (Beijing) Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1.97. Hence, Biocytogen Pharmaceuticals (Beijing) Co's PS Ratio for today is 4.51.

The historical rank and industry rank for Biocytogen Pharmaceuticals (Beijing) Co's PS Ratio or its related term are showing as below:

HKSE:02315' s PS Ratio Range Over the Past 10 Years
Min: 3.35   Med: 13.13   Max: 24.77
Current: 4.49

During the past 4 years, Biocytogen Pharmaceuticals (Beijing) Co's highest PS Ratio was 24.77. The lowest was 3.35. And the median was 13.13.

HKSE:02315's PS Ratio is ranked better than
70.21% of 997 companies
in the Biotechnology industry
Industry Median: 9.07 vs HKSE:02315: 4.49

Biocytogen Pharmaceuticals (Beijing) Co's Revenue per Sharefor the six months ended in Dec. 2023 was HK$1.07. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1.97.

During the past 12 months, the average Revenue per Share Growth Rate of Biocytogen Pharmaceuticals (Beijing) Co was 25.80% per year. During the past 3 years, the average Revenue per Share Growth Rate was 37.50% per year.

During the past 4 years, Biocytogen Pharmaceuticals (Beijing) Co's highest 3-Year average Revenue per Share Growth Rate was 37.50% per year. The lowest was 37.50% per year. And the median was 37.50% per year.

Back to Basics: PS Ratio


Biocytogen Pharmaceuticals (Beijing) Co PS Ratio Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co PS Ratio Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23
PS Ratio
- - 16.39 6.08

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
PS Ratio Get a 7-Day Free Trial - - 16.39 - 6.08

Competitive Comparison of Biocytogen Pharmaceuticals (Beijing) Co's PS Ratio

For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocytogen Pharmaceuticals (Beijing) Co's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocytogen Pharmaceuticals (Beijing) Co's PS Ratio distribution charts can be found below:

* The bar in red indicates where Biocytogen Pharmaceuticals (Beijing) Co's PS Ratio falls into.



Biocytogen Pharmaceuticals (Beijing) Co PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Biocytogen Pharmaceuticals (Beijing) Co's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=8.87/1.968
=4.51

Biocytogen Pharmaceuticals (Beijing) Co's Share Price of today is HK$8.87.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biocytogen Pharmaceuticals (Beijing) Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1.97.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Biocytogen Pharmaceuticals (Beijing) Co  (HKSE:02315) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Biocytogen Pharmaceuticals (Beijing) Co PS Ratio Related Terms

Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Business Description

Traded in Other Exchanges
Address
12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC) and other solid tumors.
Executives
Bvcf Realization Fund, L.p. 2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong You Xian Gong Si 2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong Kong Gu You Xian Gong Si 2201 Interest of corporation controlled by you
Prowell Ventures Pte Ltd 2201 Interest of corporation controlled by you
Gic Special Investments Private Limited 2102 Investment manager
Gic Private Limited 2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Yang Zhi 2201 Interest of corporation controlled by you
Innoveda Medtech, Ltd. 2201 Interest of corporation controlled by you
Ni Jian
Bvcf Realization Fund Gp, Ltd. 2201 Interest of corporation controlled by you
Bioveda China Fund Ii Rmb, Limited 2101 Beneficial owner
Cmbi Private Equity Series Spc 2201 Interest of corporation controlled by you
Cmb International Private Investment Limited 2201 Interest of corporation controlled by you
Cmb International Investment Management Limited 2201 Interest of corporation controlled by you

Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Headlines

No Headlines